Facetten
Zugriff
Einrichtung
Medientyp
- Text 52
Karte
Erscheinungsjahr
Autor/in
- Weisel, Katja
- Moreau, Philippe 7
- Bokemeyer, Carsten 6
- Goldschmidt, Hartmut 6
- Cavo, Michele 5
- alle zeigen
Sprache
52 Einträge gefunden
-
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Selective elimination of immunosuppressive T cells in patients with multiple myeloma
- Awwad, Mohamed H S
- Mahmoud, Abdelrahman
- Bruns, Heiko
- Echchannaoui, Hakim
- Kriegsmann, Katharina
- Lutz, Raphael
- Raab, Marc S
-
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
- Dimopoulos, Meletios
- Weisel, Katja
- Moreau, Philippe
- Anderson, Larry D
- White, Darrell
- San-Miguel, Jesus
- Sonneveld, Pieter
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
- Nooka, Ajay K
- Weisel, Katja
- van de Donk, Niels Wcj
- Routledge, David
- Otero, Paula Rodriguez
- Song, Kevin
- Quach, Hang
-
-
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
- Weisel, Katja
- Mateos, Maria-Victoria
- Gay, Francesca
- Delforge, Michel
- Cook, Gordon
- Szabo, Zsolt
- Desgraz, Renaud
-
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
- Chari, Ajai
- Munder, Markus
- Weisel, Katja
- Jenner, Matthew
- Bygrave, Ceri
- Petrucci, Maria Teresa
- Boccadoro, Mario
-
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
2021 - Forschungsinformationssystem des UKE - frei zugänglich -
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
- Rodriguez-Otero, Paula
- Ayers, Dieter
- Cope, Shannon
- Davies, Faith E
- Delforge, Michel
- Mojebi, Ali
- Jansen, Jeroen P
-
-
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- Dimopoulos, Meletios
- Quach, Hang
- Mateos, Maria-Victoria
- Landgren, Ola
- Leleu, Xavier
- Siegel, David
- Weisel, Katja
-
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- Mateos, Maria-Victoria
- Spencer, Andrew
- Nooka, Ajay K
- Pour, Ludek
- Weisel, Katja
- Cavo, Michele
- Laubach, Jacob P
-
-
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
- Raab, Marc S
- Engelhardt, Monika
- Blank, Antje
- Goldschmidt, Hartmut
- Agis, Hermine
- Blau, Igor W
- Einsele, Hermann
-
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
- Dimopoulos, Meletios A
- Niesvizky, Ruben
- Weisel, Katja
- Siegel, David S
- Hajek, Roman
- Mateos, María-Victoria
- Cavo, Michele
-
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
- Weisel, Katja
- Dimopoulos, Meletios
- Moreau, Philippe
- Yagci, Munci
- Larocca, Alessandra
- Kanate, Abraham S
- Vural, Filiz
-
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
- Ludwig, Heinz
- Pönisch, Wolfram
- Knop, Stefan
- Egle, Alexander
- Hinke, Axel
- Schreder, Martin
- Lechner, Daniel
-